L dihydroorotic acid

Manufactured by Merck Group

Sourced in United States

L-Dihydroorotic acid is a chemical compound that serves as a key intermediate in the biosynthesis of pyrimidine nucleotides, which are essential components of nucleic acids such as DNA and RNA. It is utilized as a laboratory reagent for various biochemical and cell biology applications.

Automatically generated - may contain errors

Lab products found in correlation

3 protocols using l dihydroorotic acid

Synthesis and Characterization of Pyrido[3,4-b]indole Derivatives

Check if the same lab product or an alternative is used in the 5 most similar protocols

K‐234 (phenyl 6‐chloro‐1‐(4‐chlorophenyl)‐1, 3, 4, 9‐tetrahydro‐2H‐pyrido[3,4‐b]indole‐2‐carboxylate), PTC299 (4‐chlorophenyl (S)‐6‐chloro‐1‐(4‐methoxyphenyl)‐1,3,4,9‐tetrahydro‐2H‐pyrido[3,4‐b]indole‐2‐carboxylate), and K‐733 (phenyl 6‐chloro‐1‐(4‐(5‐methyl‐1,2,4‐oxadiazol‐3‐yl)phenyl)‐1,3,4,9‐tetrahydro‐2H‐pyrido[3,4‐b]indole‐2‐carboxylate) were synthesized by Kyowa Kirin (Shizuoka, Japan). Their chemical structures are shown in Figure 1. L‐Dihydroorotic acid was purchased from Sigma‐Aldrich (St. Louis, MO, USA). Orotic acid and 5‐fluoroorotic acid were purchased from Tokyo Chemical Industry (Tokyo, Japan). TransIT‐LT1 reagent was purchased from Mirus Bio (Madison, WI, USA). All other reagents were obtained from Tokyo Chemical Industry and FUJIFILM Wako Pure Chemical Industries (Osaka, Japan), or Sigma‐Aldrich, unless otherwise indicated.

Watanabe M., Kosaka H., Sugawara M., Maemoto M., Ono Y., Uemori T., Shizu R, & Yoshinari K. (2023). Screening for DAX1/EWS‐FLI1 functional inhibitors identified dihydroorotate dehydrogenase as a therapeutic target for Ewing's sarcoma. Cancer Medicine, 12(8), 9802-9814.

+ Open protocol

+ Expand

Metabolic Assay Reagent Sources

Check if the same lab product or an alternative is used in the 5 most similar protocols

ADP monopotassium salt dehydrate, ascorbic acid (ascorbate), l-dihydroorotic acid (DHO), sn-glycerol 3-phosphate bis(cyclohexylammonium) salt (G3P), glucose, l-glutamic acid potassium salt monohydrate (glutamate), malic acid (malate), pyruvic acid (pyruvate), succinic acid (succinate), N,N,N′,N′-tetramethyl-p-phenylenediamine dihydrochloride (TMPD), 2-deoxy-d-glucose (2-DG), antimycin A, atovaquone, carbonyl cyanide 4-(trifluoromethoxy)-phenylhydrazone (FCCP), and decoquinate were purchased from Sigma-Aldrich (St. Louis, MO). Oligomycin A was purchased from Calbiochem (San Diego, CA). BZT-1, genz-669178, and IDI-5918 were provided by Prof. Ralph Mazitschek (Massachusetts General Hospital, MA), Genzyme (Waltham, MA), and the Broad Institute (Cambridge, MA), respectively.

Sakata-Kato T, & Wirth D.F. (2016). A Novel Methodology for Bioenergetic Analysis of Plasmodium falciparum Reveals a Glucose-Regulated Metabolic Shift and Enables Mode of Action Analyses of Mitochondrial Inhibitors. ACS infectious diseases, 2(12), 903-916.

+ Open protocol

+ Expand

Antimalarial Compound Screening Protocol

Check if the same lab product or an alternative is used in the 5 most similar protocols

L-Dihydroorotic acid (DHO), CoQ_D, DCIP, antimycin A, atovaquone (ATV), mefloquine (MQ), artemisinin, dihydroartemisinin (DHA), and proguanil were purchased from Sigma-Aldrich (St. Louis, MO). Genz-669178, was kindly provided by Genzyme, a Sanofi Company (Waltham, MA). IDI-6273 was purchased from ChemDiv. DSM1 and DSM74 were prepared following the literature procedure^{28 (link)} and were recrystallized from ethanol. 1H NMR spectra matched that reported, and HPLC analysis indicated >95% purity.

Ross L.S., Lafuente-Monasterio M.J., Sakata-Kato T., Mandt R.E., Gamo F.J., Wirth D.F, & Lukens A.K. (2018). Identification of Collateral Sensitivity to Dihydroorotate Dehydrogenase Inhibitors in Plasmodium falciparum. ACS Infectious Diseases, 4(4), 508-515.

+ Open protocol

+ Expand

About PubCompare

Our mission is to provide scientists with the largest repository of trustworthy protocols and intelligent analytical tools, thereby offering them extensive information to design robust protocols aimed at minimizing the risk of failures.

We believe that the most crucial aspect is to grant scientists access to a wide range of reliable sources and new useful tools that surpass human capabilities.

However, we trust in allowing scientists to determine how to construct their own protocols based on this information, as they are the experts in their field.

Ready to get started?

Revolutionizing how scientists
search and build protocols!